Table 1:

List of Health Canada–approved targeted agents by the genes harbouring the sensitizing alteration (7)

Affected geneEstimated prevalence in NSCLC tumours,* %Approved targeted therapies
KRAS (G12C)12–15Sotorasib
EGFR12–15Afatinib, amivantamab, dacomitinib, erlotinib, gefinitib, osimertinib†
ALK2–7Alectinib, brigatinib, ceritinib, crizotinib, lorlatinib
BRAF2–4Dabrafenib–tramentinib
MET3Capmatinib, tepotinib
ROS11–2Crizotinib, entrectinib
RET1–2Pralsetinib, selpercatinib
NTRK< 1Entrectinib, larotrectinib

  • Note: NSCLC = non–small cell lung carcinoma.

  • ↵* Prevalence varies significantly by ethnicity.

  • ↵† Osimertinib is approved as adjuvant therapy after surgical resection.